1. A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.
- Author
-
Loebel, Antony, Koblan, Kenneth S., Tsai, Joyce, Deng, Ling, Fava, Maurizio, Kent, Justine, and Hopkins, Seth C.
- Subjects
- *
BIPOLAR disorder , *AMISULPRIDE , *HYPOMANIA , *SEROTONIN receptors , *PROOF of concept , *SECONDARY analysis , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *PSYCHOLOGICAL tests , *RANDOMIZED controlled trials , *BLIND experiment , *MENTAL depression , *CLASSIFICATION of mental disorders - Abstract
Background: Non-racemic amisulpride (SEP-4199) is an 85:15 ratio of aramisulpride:esamisulpride with a 5-HT7 and D2 receptor binding profile optimized for the treatment of bipolar depression. The aim of this study was to evaluate the efficacy and safety of SEP-4199 for the treatment of bipolar depression.Methods: Patients meeting DSM-5 criteria for bipolar I depression were randomized to 6 weeks of double-blind, placebo-controlled treatment with SEP-4199 200 mg/d or 400 mg/d. The primary endpoint was change in the Montgomery-Asberg Depression Rating Scale (MADRS) at Week 6. The primary efficacy analysis population consisted of patients in Europe and US (n = 289); the secondary efficacy analysis population (ITT; n = 337) included patients in Japan.Results: Endpoint improvement in MADRS total score was observed on both the primary analysis for SEP-4199 200 mg/d (P = 0.054; effect size [ES], 0.31) and 400 mg/d (P = 0.054; ES, 0.29), and on the secondary (full ITT) analysis for SEP-4199 200 mg/d (P = 0.016; ES, 0.34) and 400 mg/d (P = 0.024; ES, 0.31). Study completion rates were 81% on SEP-4199 200 mg/d, 88% on 400 mg/d, and 86% on placebo. SEP-4199 had low rates of individual adverse events (<8%) and minimal effects on weight and lipids; median increases in prolactin were +83.6 μg/L on 200 mg/d, +95.2 μg/L on 400 mg/d compared with 0.0 μg/L on placebo.Limitations: The study excluded patients with bipolar II depression and serious psychiatric or medical comorbidity.Conclusion: Study results provide preliminary proof of concept, needing confirmation in subsequent randomized trials, for the efficacy of non-racemic amisulpride in bipolar depression. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF